Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Non Operating Income (2023 - 2025)

Contineum Therapeutics has reported Non Operating Income over the past 3 years, most recently at $8.2 million for Q4 2025.

  • Quarterly results put Non Operating Income at $8.2 million for Q4 2025, up 230.18% from a year ago — trailing twelve months through Dec 2025 was $14.6 million (up 68.89% YoY), and the annual figure for FY2025 was $8.1 million, down 6.43%.
  • Non Operating Income for Q4 2025 was $8.2 million at Contineum Therapeutics, up from $2.4 million in the prior quarter.
  • Over the last five years, Non Operating Income for CTNM hit a ceiling of $8.2 million in Q4 2025 and a floor of -$76000.0 in Q2 2023.
  • Median Non Operating Income over the past 3 years was $1.9 million (2024), compared with a mean of $2.1 million.
  • Biggest five-year swings in Non Operating Income: soared 7619.44% in 2024 and later fell 10.97% in 2025.
  • Contineum Therapeutics' Non Operating Income stood at $1.7 million in 2023, then skyrocketed by 42.15% to $2.5 million in 2024, then surged by 230.18% to $8.2 million in 2025.
  • The last three reported values for Non Operating Income were $8.2 million (Q4 2025), $2.4 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.